mRNA 1647
Alternative Names: CMV vaccine - Moderna Therapeutics; Cytomegalovirus vaccine - Moderna Therapeutics; mRNA-1647Latest Information Update: 28 Mar 2024
At a glance
- Originator Moderna Therapeutics
- Class Cytomegalovirus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Cytomegalovirus infections
Most Recent Events
- 15 Mar 2024 ModernaTX withdraws a phase-II trials in Cytomegalovirus infections (Prevention) in USA (IM), prior to enrolment (NCT06133010)
- 08 Jan 2024 Moderna Therapeutics completes enrolment in the phase III CMVictory trial for cytomegalovirus infections (Prevention) in USA (IM) (NCT05085366)
- 15 Nov 2023 ModernaTX plans a phase II trial for Cytomegalovirus Infection in the US (IM, Injection) (NCT06133010)